title: Fluparoxan: A Comprehensive Review of its Discovery, Adrenergic and CNS Activity and Treatment of Cognitive Dysfunction in Central Neurodegenerative Diseases.
abstract: BACKGROUND
  The design, medicinal chemistry, pharmacokinetics and development of the highly selective α2-adrenoceptor antagonist fluparoxan are reviewed.
  
  
  METHODS
  The drug's activity and selectivity in vitro, its efficacy in animals and its excellent oral pharmacokinetics and central α2-adrenoceptor antagonist activity in man, are evaluated as well as its ability to increase extracellular levels of noradrenaline, dopamine and acetylcholine in vivo.
  
  
  CONCLUSIONS
  Furthermore, its potential for the treatment of central neurodegenerative diseases is highlighted, in particular its improvement of cognitive dysfunction in schizophrenia and in models of Alzheimer's disease.
authors.affiliation: DrugMolDesign, 15 Temple Grove, London NW11 7UA, United Kingdom.
authors.forename: Alan D
authors.initials: AD
authors.lastname: Borthwick
mesh_terms: D018663:Adrenergic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D002490:Central Nervous System / Q000187:drug effects* / Q000473:pathology; D060825:Cognitive Dysfunction / Q000188:drug therapy* / Q000473:pathology; D055808:Drug Discovery; D006801:Humans; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000473:pathology; D010883:Piperoxan / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D011758:Pyrroles / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*
chemical_list: D018663:Adrenergic Agents; D011758:Pyrroles; D010883:Piperoxan; C065161:fluparoxan
keywords: Alzheimer's; depression; fluparoxan; schizophrenia; α2-adrenoceptor antagonist